Pembrolizumab: tested in a combination

521 studies: another drug in the study is under test too. Page 4 of 6. Open to participants first (187), then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results postedReport a problem
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results postedReport a problem
• Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for TransplantCompletedNCT02771197Phase 2Results postedReport a problem
• Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast CancerCompletedNCT02768701Phase 2Results postedReport a problem
• Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast CancerActive, not recruitingNCT02752685Phase 2Results postedReport a problem
• Pembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaActive, not recruitingNCT02743819Phase 2Results postedReport a problem
• Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck CancerCompletedNCT02718820Phase 1/2Results postedReport a problem
• Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02713373Phase 1/2Results postedReport a problem
• Pembrolizumab and GM-CSF in Biliary CancerCompletedNCT02703714Phase 2Results postedReport a problem
• Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant TherapyCompletedNCT02690558Phase 2Results postedReport a problem
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)CompletedNCT02681549Phase 2Results postedReport a problem
• Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue SarcomasCompletedNCT02636725Phase 2Results postedReport a problem
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedNCT02626000Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)TerminatedNCT02625961Phase 2Results postedReport a problem
• Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)CompletedNCT02622074Phase 1Results postedReport a problem
• Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLCCompletedNCT02591615Phase 2Results postedReport a problem
• Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial CancerCompletedNCT02581982Phase 2Results postedReport a problem
• Pembrolizumab and Paclitaxel in Refractory Small Cell Lung CancerCompletedNCT02551432Phase 2Results postedReport a problem
• Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryCompletedNCT02538510Phase 1/2Results postedReport a problem
• Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin LymphomaTerminatedNCT02535247Phase 1/2Results postedReport a problem
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results postedReport a problem
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results postedReport a problem
• Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaActive, not recruitingNCT02446457Phase 2Results postedReport a problem
• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results postedReport a problem
• Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II TrialCompletedNCT02406781Phase 2Results postedReport a problem
• Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibCompletedNCT02364609Phase 1Results postedReport a problem
• Pembrolizumab +/- Bevacizumab for Recurrent GBMCompletedNCT02337491Phase 2Results postedReport a problem
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results postedReport a problem
• Pembrolizumab and Monoclonal Antibody Therapy in Advanced CancerTerminatedNCT02318901Phase 1/2Results postedReport a problem
• A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal CancerCompletedNCT02260440Phase 2Results postedReport a problem
• A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell CancerCompletedNCT02133742Phase 1Results postedReport a problem
• A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)CompletedNCT02130466Phase 1/2Results postedReport a problem
• Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)CompletedNCT02089685Phase 1/2Results postedReport a problem
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaCompletedNCT01993719Phase 2Results postedReport a problem
• A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)CompletedNCT01953692Phase 1Results postedReport a problem
• Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentCompletedNCT07537985Not applicableReport a problem
• Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerActive, not recruitingNCT07523763Phase 2Report a problem
• Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesWithdrawnNCT07011849Phase 2Report a problem
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsActive, not recruitingNCT06906822Phase 2Report a problem
• Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCCSuspendedNCT06860386Phase 2Report a problem
• Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerActive, not recruitingNCT06632327Phase 3Report a problem
• Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast CancerCompletedNCT06604858Phase 2Report a problem
• Perioperative Immunotherapy for NSCLC (ECTOP-1030)WithdrawnNCT06572722Phase 2Report a problem
• Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomasActive, not recruitingNCT06557889Phase 2Report a problem
• Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal CancerStatus unknownNCT06550453Phase 4Report a problem
• Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT06242834Phase 2Report a problem
• A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETsActive, not recruitingNCT06232564Phase 2Report a problem
• Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerActive, not recruitingNCT06178445Phase 2Report a problem
• Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant PembrolizumabWithdrawnNCT06116578Phase 2Report a problem
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2Report a problem
• Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerActive, not recruitingNCT06055465Phase 2Report a problem
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06027268Phase 2Report a problem
• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2Report a problem
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2Report a problem
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2Report a problem
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2Report a problem
• POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1Report a problem
• Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsActive, not recruitingNCT05751187Phase 2Report a problem
• Neoadjuvant Chemoimmunotherapy in Recurrent GlioblastomaStatus unknownNCT05700955Phase 1Report a problem
• A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Active, not recruitingNCT05675579Phase 2Report a problem
• Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCActive, not recruitingNCT05645380Phase 2Report a problem
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3Report a problem
• EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaCompletedNCT05619913Phase 2Report a problem
• Safety and Efficacy of TRPP Therapy in Glioblastoma MultiformeStatus unknownNCT05589961Early Phase 1Report a problem
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerActive, not recruitingNCT05585814Phase 2Report a problem
• Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney CancerActive, not recruitingNCT05578664Phase 2Report a problem
• Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCCompletedNCT05549037Phase 3Report a problem
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2Report a problem
• Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder CancerActive, not recruitingNCT05535218Phase 2Report a problem
• Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaActive, not recruitingNCT05524935Phase 2Report a problem
• Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/OverexpressionWithdrawnNCT05512182Phase 2Report a problem
• Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2Report a problem
• Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaCompletedNCT05504720Phase 2Report a problem
• Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnNCT05493618Phase 1/2Report a problem
• Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2Report a problem
• Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and AboveActive, not recruitingNCT05404945Phase 2Report a problem
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2Report a problem
• Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2Report a problem
• Pembrolizumab Plus Olaparib in LA-HNSCCActive, not recruitingNCT05366166Phase 2Report a problem
• Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After ChemotherapyStatus unknownNCT05322187Phase 2/3Report a problem
• Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2Report a problem
• Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2Report a problem
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)CompletedNCT05282901Phase 2Report a problem
• A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1Report a problem
• Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ AdenocarcinomaCompletedNCT05268510Phase 2Report a problem
• Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2Report a problem
• Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2Report a problem
• Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)WithdrawnNCT05255666Phase 2Report a problem
• Docetaxel/Pembrolizumab in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05252429Phase 2Report a problem
• Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2Report a problem
• Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).Status unknownNCT05201612Phase 2Report a problem
• Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerWithdrawnNCT05177796Phase 2Report a problem
• Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsStatus unknownNCT05175235Phase 1/2Report a problem
• Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2Report a problem
• A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaCompletedNCT05156268Phase 2Report a problem
• A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2Report a problem
• Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2Report a problem
• Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant ChemoradiotherapyStatus unknownNCT05103501Phase 2Report a problem
• Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2Report a problem
• Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerActive, not recruitingNCT05093231Phase 2Report a problem

← Pembrolizumab